Base of tongue squamous cell carcinomas, outcome depending on treatment strategy and p16 status. A population-based study from the Swedish Head and Neck Cancer Register

References

• Attner P, Du J, Nasman A, et al. The role of human papillomavirus in the increased incidence of base of tongue cancer. Int J Cancer. 2010;126(12):2879–2884.
   PubMed Web of Science ®Google Scholar
• Attner P, Du J, Nasman A, et al. Human papillomavirus and survival in patients with base of tongue cancer. Int J Cancer. 2011;128(12):2892–2897.
   PubMed Web of Science ®Google Scholar
• Sobin LH, Gospodarowicz MK, Wittekind C, et al. TNM classification of malignant tumours. 7th ed. Chichester (UK); West Sussex (UK); Hoboken (NJ): Wiley-Blackwell; 2010.
   Google Scholar
• van Gysen K, Stevens M, Guo L, et al. Validation of the 8(th) edition UICC/AJCC TNM staging system for HPV associated oropharyngeal cancer patients managed with contemporary chemo-radiotherapy. BMC Cancer. 2019;19(1):674.
   PubMed Web of Science ®Google Scholar
• Brierley J, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th ed. Chichester (UK); West Sussex (UK); Hoboken (NJ): John Wiley & Sons, Inc.; 2017.
   Google Scholar
• Wurdemann N, Wagner S, Sharma SJ, et al. Prognostic impact of AJCC/UICC 8th edition new staging rules in oropharyngeal squamous cell carcinoma. Front Oncol. 2017;7:129.
   PubMed Web of Science ®Google Scholar
• SweHNCR. The Swedish Head and Neck Cancer Register. Gothenburg (Sweden): Regional Cancer Centre West; 2020. https://www.cancercentrum.se/samverkan/cancerdiagnoser/huvud-och-hals/kvalitetsregister.
   Google Scholar
• Nauta IH, Rietbergen MM, van Bokhoven A, et al. Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in The Netherlands and the importance of additional HPV DNA testing. Ann Oncol. 2018;29(5):1273–1279.
   PubMed Web of Science ®Google Scholar
• Anantharaman D, Abedi-Ardekani B, Beachler DC, et al. Geographic heterogeneity in the prevalence of human papillomavirus in head and neck cancer. Int J Cancer. 2017;140(9):1968–1975.
   PubMed Web of Science ®Google Scholar
• O’Sullivan B, Huang SH, Su J, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the international collaboration on oropharyngeal cancer network for staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17(4):440–451.
   PubMed Web of Science ®Google Scholar
• Bussu F, Ragin C, Boscolo-Rizzo P, et al. HPV as a marker for molecular characterization in head and neck oncology: looking for a standardization of clinical use and of detection method(s) in clinical practice. Head Neck. 2019;41(4):1104–1111.
   PubMed Web of Science ®Google Scholar
• Hammarstedt L, Holzhauser S, Zupancic M, et al. The value of p16 and HPV DNA in non-tonsillar, non-base of tongue oropharyngeal cancer. Acta Otolaryngol. 2021;141(1):89–94.
   PubMed Web of Science ®Google Scholar
• Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342(25):1878–1886.
   PubMed Web of Science ®Google Scholar
• Bergqvist D, Bjorck M, Sawe J, et al. Randomized trials or population-based registries. Eur J Vasc Endovasc Surg. 2007;34(3):253–256.
   PubMed Web of Science ®Google Scholar
• Silva SR, Martin B, Choi M, et al. National cancer database analysis of the effect of brachytherapy on overall survival in patients with base of tongue cancer. Head Neck. 2019;41(5):1184–1192.
   PubMed Web of Science ®Google Scholar
• Bussu F, Tagliaferri L, Mattiucci G, et al. HDR interventional radiotherapy (brachytherapy) in the treatment of primary and recurrent head and neck malignancies. Head Neck. 2019;41(6):1667–1675.
   PubMed Web of Science ®Google Scholar
• Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011;100(1):33–40.
   PubMed Web of Science ®Google Scholar
• Patel RR, Ludmir EB, Augustyn A, et al. De-intensification of therapy in human papillomavirus associated oropharyngeal cancer: a systematic review of prospective trials. Oral Oncol. 2020;103:104608.
   PubMed Web of Science ®Google Scholar
• Price KAR, Nichols AC, Shen CJ, et al. Novel strategies to effectively de-escalate curative-intent therapy for patients with HPV-associated oropharyngeal cancer: current and future directions. Am Soc Clin Oncol Educ Book. 2020;40:1–13.
   PubMedGoogle Scholar
• Gebre-Medhin M, Brun E, Engstrom P, et al. ARTSCAN III: a randomized phase III study comparing chemoradiotherapy with cisplatin versus cetuximab in patients with locoregionally advanced head and neck squamous cell cancer. J Clin Oncol. 2021;39(1):38–47.
   PubMed Web of Science ®Google Scholar
• Yom SS, Torres-Saavedra P, Caudell JJ, et al. NRG-HN002: a randomized phase II trial for patients with p16-positive, non-smoking-associated, locoregionally advanced oropharyngeal cancer. Int J Radiat Oncol. 2019;105(3):684–685.
   Web of Science ®Google Scholar
• Yoshida EJ, Luu M, Mallen-St Clair J, et al. Stage I HPV-positive oropharyngeal cancer: should all patients receive similar treatments? Cancer. 2020;126(1):58–66.
   PubMed Web of Science ®Google Scholar
• Ozcan-Wahlbrink M, Schifflers C, Riemer AB. Enhanced radiation sensitivity of human papillomavirus-driven head and neck cancer. Front Immunol. 2019;10(2831):2831.
   PubMedGoogle Scholar
• Jaber JJ, Murrill L, Clark JI, et al. Robust differences in p16-dependent oropharyngeal squamous cell carcinoma distant metastasis: implications for targeted therapy. Otolaryngol Head Neck Surg. 2015;153(2):209–217.
   PubMed Web of Science ®Google Scholar